22 Jul The Biggest DSCSA Mistakes Companies Still Make in 2026

Posted at 08:00h in News by

Even after the official DSCSA requirements took effect, many pharmaceutical companies across the United States are still struggling with operational gaps related to traceability, EPCIS data exchange, and compliance workflows.

The challenge is no longer simply understanding the regulation. Today, the real difficulty lies in managing the growing complexity of pharmaceutical operations while maintaining speed, accuracy, and full visibility across the supply chain.

For many distributors, manufacturers, and dispensers, compliance issues no longer come from a lack of effort. Instead, they often result from outdated processes, disconnected systems, poor data visibility, or the assumption that serialization alone is enough.

Here are some of the biggest DSCSA mistakes companies still make, and why they continue to create operational risks in 2026.

  1. Believing Serialization Alone Equals Compliance

One of the most common misconceptions in the industry is the idea that serialization automatically means DSCSA compliance.

Serialization is only one piece of the process. DSCSA also requires interoperable electronic tracing, accurate product verification, proper EPCIS data exchange, and the ability to quickly respond to investigations or verification requests.

Companies that focus only on serialized labels without ensuring end-to-end traceability often discover compliance gaps much later, usually when operational issues begin to appear.

  1. Relying Too Heavily on Manual Processes

Despite the industry’s digital transformation, many pharmaceutical operations still depend on spreadsheets, manual inventory checks, email-based workflows, or disconnected systems.

At smaller volumes, these processes may seem manageable. But as operations grow, manual work quickly becomes a liability.

Human error, duplicate data entry, delayed updates, and missing information can directly impact shipment accuracy, inventory visibility, and EPCIS validation.

Modern pharmaceutical operations require systems that can automate critical workflows while maintaining accuracy and traceability in real time.

  1. Poor EPCIS Data Validation

EPCIS data issues continue to be one of the largest operational challenges under DSCSA.

Incomplete files, inconsistent product information, invalid serial numbers, formatting problems, and integration failures can all disrupt operations and delay shipments.

In many cases, companies only discover these problems after receiving rejected files from trading partners or during internal investigations.

Without proper validation processes and system controls, small data inconsistencies can quickly become much larger operational problems.

  1. Lack of Real-Time Inventory Visibility

Inventory visibility has become essential in pharmaceutical distribution.

Companies need to know not only what inventory exists, but also:

  • what is available,
  • what is reserved,
  • what has already been allocated,
  • and which serialized products are tied to specific shipments.

Without real-time visibility, businesses increase the risk of shipping delays, overselling inventory, fulfillment mistakes, and compliance complications.

This becomes even more critical when dealing with serialized inventory and EPCIS-related workflows.

  1. Waiting Until Problems Happen

Another major mistake is treating compliance as a reactive process instead of a proactive strategy.

Many companies only revisit their workflows after:

  • shipment rejections,
  • EPCIS failures,
  • customer complaints,
  • audit findings,
  • or operational disruptions.

By that point, the issue often affects multiple departments and creates unnecessary pressure across the organization.

Companies that continuously evaluate their processes, systems, and data quality are typically far more prepared to handle long-term DSCSA requirements efficiently.

  1. Using Systems That Were Never Built for Pharma

Not every ERP or operational system is designed for pharmaceutical distribution.

Generic systems often require heavy customization to support:

  • serialization,
  • EPCIS workflows,
  • traceability requirements,
  • inventory controls,
  • and regulatory reporting.

As compliance requirements continue evolving, companies using systems that were not built specifically for pharmaceutical operations frequently encounter scalability and integration limitations.

Purpose-built platforms designed around pharmaceutical workflows can significantly reduce operational complexity while improving visibility, compliance readiness, and day-to-day efficiency.

Compliance Is Now an Operational Strategy

DSCSA compliance is no longer just a regulatory checkbox. It has become part of how pharmaceutical companies operate, scale, and maintain trust across the supply chain.

The organizations that are succeeding in 2026 are not simply reacting to regulations. They are investing in stronger processes, better visibility, integrated systems, and more reliable data management.

Because in today’s pharmaceutical environment, compliance is no longer separate from operations, it is operations.

Print page
0 Likes